BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency
Executive Summary
New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.
You may also be interested in...
With Increasing New Drug INDs Projected, How Much More Workload Can US FDA Handle?
Meanwhile, the biosimilars program is expecting essentially flat application numbers, but more manufacturing supplements and more development meetings, which likely is an indication of the sector’s flourishing in the US.
US FDA Pandemic Performance: On-Time Decision Rates Improve; COVID Applications, Supplements Drop
Biosimilars continue their erratic behavior, with the low numbers driving big swings.
Remote Methods Drove Most US FDA Enforcement Actions In FY 2021
Product sampling and remote records requests accounted for most import alerts and drug GMP warning letters over the past year – and may play key role post-pandemic.